Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.

Cath EberleinStuart Charles WilliamsonLorna HopcroftSusana RosJennifer I MossJames KerrThomas A KirklandElza C de BruinShanade DunnBrandon WillisSarah J RossClaire RooneySimon T Barry

Published in: British journal of cancer (2024)

Capivasertib can enhance anti-tumour effects of docetaxel by targeting residual docetaxel-persister cells, independent of PTEN status, to induce apoptosis and DNA damage in part through GSK3β.

Keyphrases

cell cycle arrest
pi k akt
signaling pathway
prostate cancer
dna damage
induced apoptosis
oxidative stress
cell proliferation
locally advanced
cell death
endoplasmic reticulum stress
radical prostatectomy
squamous cell carcinoma
rectal cancer